AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03306030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Three times dose of 4L PEG
Description: The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
Study NCT02856386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: polyphenol supplement
Description: 8 mL once daily
Study NCT03302780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: BreEStim will applied for 10 to 20 minutes.
Study NCT03952286 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ED-Dispensing home and school supervision
Description: 1. Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department),~2. 360 ug of budesonide inhalation powder once-daily for at-home use, and~3. albuterol sulfate as needed for relief of acute respiratory symptoms.
Study NCT03952286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ED-Dispensing home and school supervision
Description: 1. Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department),~2. 360 ug of budesonide inhalation powder once-daily for at-home use, and~3. albuterol sulfate as needed for relief of acute respiratory symptoms.
Study NCT03302780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS active
Description: tDCS will be applied for 20 minutes.
Study NCT03302780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS sham
Study NCT02375386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
Study NCT02375386 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic touch
Description: Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
Study NCT02375386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Both groups will receive an fMRI.
Study NCT02375386 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: fMRI
Description: Both groups will receive an fMRI.
Study NCT02375386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Sensitivity Testing
Description: Both groups will receive an Pain Sensitivity Testing
Study NCT02375386 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pain Sensitivity Testing
Description: Both groups will receive an Pain Sensitivity Testing
Study NCT02375386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Both groups will receive Questionnaires
Study NCT02375386 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaires
Description: Both groups will receive Questionnaires
Study NCT04177030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isopesticide dietary scheme
Description: All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met.
Study NCT02375386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Impairment
Description: Both groups will receive testing on physical impairment.
Study NCT02375386 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Physical Impairment
Description: Both groups will receive testing on physical impairment.
Study NCT01608269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abacavir/Lamivudine
Description: one tablet once a day
Study NCT01093989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulphate Syrup
Description: Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
Study NCT01093989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous Sulphate Syrup
Description: Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
Study NCT00699296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589)
Description: 20mg/day p.o. on three times-a- week
Study NCT01208337 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab
Description: Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
Study NCT02535611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
Study NCT02535611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Beside the usual treatment for ischemic stroke this group will be treated by memantine.
Study NCT02910778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.
Study NCT02910778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
Study NCT00309101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral
Study NCT02910778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study NCT02910778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor
Study NCT04990570 — intervention group
Intervention type: OTHER
Intervention: Telemedicine in the form Virtual clinic via video consultation
Description: Pediatric patients, with age ranging from 1 month-14 years, with surgical problems, encountered during the era of Covid-19 pandemic.~Some of them seen at the OPD clinic, while the majority failed to attend because of Covid-19 associated lock-down and Curfew, thus, rendering their approach to the service.~Telemedicine, in the form of Virtual clinic, was utilized to address the distressing problem of difficult approach of patients to the pedia surgery OPD because of Covid-19 pandemic restrictive regulatory precautions, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship \& encounter.
Study NCT02175550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NR CC
Study NCT00631319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Description: hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
Study NCT00631319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05505058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio-visual material
Description: Participants were randomized to receive a paper-based conventional material or to watch a 4-min video. Materials both included legal information required by the Swiss Federal Act on Research involving Human Beings.
Study NCT05505058 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio-visual material
Description: Participants were randomized to receive a paper-based conventional material or to watch a 4-min video. Materials both included legal information required by the Swiss Federal Act on Research involving Human Beings.
Study NCT01165229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine GSK1437173A
Description: Intramuscular injection
Study NCT01165229 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection.
Study NCT02088931 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treg infusion
Description: At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease \<50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
Study NCT00841191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
Study NCT02815956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous tibial nerve stimulation
Study NCT00976742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Study NCT03990350 — intervention group
Intervention type: OTHER
Intervention: Fecal Sample Collection
Description: With permission from the parent/guardian, stool collected in a sterile container will be brought within 12 hours of defecation from home or the outpatient clinic to a separate clinical laboratory where feces will be collected through use of FLOQswab brush x 3 (Copan Diagnostics, Murrieta, CA) The swabs will be pre-labeled with a de-identified code reflecting patient number, sample number, and date and the sample will be placed into dry ice then transferred to a -80 degrees Celsius freezer until retrieval by the research staff for transfer to CHOP Microbiome Center.
Study NCT03990350 — intervention group
Intervention type: OTHER
Intervention: Physical Activity Questionnaire
Description: At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Physical Activity Questionnaire (Physical Activity Questionnaire for Older Children) with the subject and parent.
Study NCT03990350 — intervention group
Intervention type: OTHER
Intervention: Food Frequency Questionnaire
Description: At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Food Frequency Questionnaire with the subject and parent.
Study NCT00841191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
Study NCT01043640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
Study NCT00841191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
Study NCT00841191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
Study NCT00841191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
Study NCT01043640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
Study NCT01043640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Administered every 6 hours: If \< or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If > 12 kg then 0.8 mg/kg/dose IV
Study NCT01043640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Description: Administered > 24 hours after last dose of busulfan.
Study NCT01043640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: 2.5 mg/kg/dose intravenous (IV_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:~* If body weight is ≤ 40 kg dosing will be 3 times daily~* If body weight is > 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).
Study NCT01043640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC>500 x 10\^6 neutrophils/L x 3 days and chimerism >90%), whichever is later.
Study NCT03983941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Total dose not to exceed 3 mg/kg of ropivacaine.
Study NCT03983941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Total dose not to exceed 3 mg/kg of ropivacaine.
Study NCT01243476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).
Study NCT01243476 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral use, daily during study treatment (104 weeks)
Study NCT02888626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microlens Array
Description: Treatment with Cutera Microlens Array Device used with the enlighten™ 532nm /1064nm/670nm laser
Study NCT01037712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir (ZELITREX)
Description: 2g, 8g/day, 4 a day 23 weeks maximum.
Study NCT01037712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03820115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder
Description: Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
Study NCT00841191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
Study NCT02043574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise
Description: Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.
Study NCT02043574 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stretching (control)
Description: Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
Study NCT01480986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan combined with cisplatin, octreotide lar
Description: Phase 1 irinotecan 180mg/m\^2，ivgtt，90min，D1 Cisplatin 50 mg/m\^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
Study NCT00608140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical mitral valvuloplasty with placement of annular ring (SMVR)
Description: Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
Study NCT00608140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT)
Description: Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
Study NCT00608140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy (OMT)
Description: Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
Study NCT02625038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUDAMED CIV-14-03-011940
Study NCT00841191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328; Anti-interleukin-6 monoclonal antibody
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H\&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
Study NCT02574377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: myDC vaccination
Study NCT02574377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: pDC vaccination
Study NCT02574377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: combined myDC/pDC vaccination